Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramelteon (Rozerem) in the treatment of sleep disturbances associated with Parkinson's disease.

Trial Profile

Ramelteon (Rozerem) in the treatment of sleep disturbances associated with Parkinson's disease.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2010

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Sleep disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2010 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top